Sentences with phrase «price at current exchange rates»

Not exact matches

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (texchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (texchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tExchange Commission (the SEC).

These risks include, in no particular order, the following: the trends toward more high - definition, on - demand and anytime, anywhere video will not continue to develop at its current pace or will expire; the possibility that our products will not generate sales that are commensurate with our expectations or that our cost of revenue or operating expenses may exceed our expectations; the mix of products and services sold in various geographies and the effect it has on gross margins; delays or decreases in capital spending in the cable, satellite, telco, broadcast and media industries; customer concentration and consolidation; the impact of general economic conditions on our sales and operations; our ability to develop new and enhanced products in a timely manner and market acceptance of our new or existing products; losses of one or more key customers; risks associated with our international operations; exchange rate fluctuations of the currencies in which we conduct business; risks associated with our CableOS ™ and VOS ™ product solutions; dependence on market acceptance of various types of broadband services, on the adoption of new broadband technologies and on broadband industry trends; inventory management; the lack of timely availability of parts or raw materials necessary to produce our products; the impact of increases in the prices of raw materials and oil; the effect of competition, on both revenue and gross margins; difficulties associated with rapid technological changes in our markets; risks associated with unpredictable sales cycles; our dependence on contract manufacturers and sole or limited source suppliers; and the effect on our business of natural disasters.

If we take the median forecast of $ US 19 / tonne at 2000 prices, add inflation and convert to CAD at current exchange rates, that works out to about $ C 25 / tonne.

At the same time, the current level of the exchange rate represents a big shift in relative prices, which should provide substantial ongoing assistance for the export sector (and the import - competing sector).

Marriott Vacation Club, a global leader in vacation ownership, has completed the sale of the hotel component of the Surfers Paradise Marriott Resort & Spa in Queensland, Australia to Bensonlily Surfers Paradise Pty Ltd for a gross sale price of $ 70 million AUD (approximately $ 50 million USD at current exchange rates).

If sellers want to buy in Bitcoins, the price will be based on the day of the offer at current value rates according to the Canadian virtual exchange and the weighted price of 12 hours.

On the other hand, for resource producers, production will be highly profitable at current exchange rates, given developments in resource prices.

With the crazy exchange rate at the moment, $ 40million euros is only 28.5 m GBP so he is well within Wenger's price range, and if he continues to improve at his current rate then this could prove to be a very solid investment for the club.

The 27 year - old has a reported price tag of # 50m and is said to have a salary bill of 10 million euros, (which as about the same as Arsene Wenger earns at the current exchange rate), but he has scored a very respectable 101 goals in his last 149 games which is not a bad rate of return, and he should be worth every penny.

At the current price and exchange rates, it's about $ 26 USD shipped to the United States and $ 36 CAD shipped to Canada.

The reproduction fabric will be priced at 184.45 Euros (roughly $ 229 at current exchange rates) per 1,000 x 1,400 mm (3.2 x 4.5 foot) sheet.

Priced from $ 446,250 (# 358,499 at current exchange rates), the SLS GT3 45th Anniversary edition will come with the option of an on - track coaching session at an AMG driving event.

The company's first concept is an electric (no surprise there) SUV (nor there), which our sister site Auto Express suggests will have a starting price of around $ 45,000, or in the region of # 33,000 at current exchange rates.

All that runs to $ 16,995, on top of the Z06's $ 79,000 base price — equivalent to around # 10,900 on top of # 50,500 at current exchange rates.

Three will be made, and they have already been snapped up, despite the Veneno's asking price — three million euros plus local taxes (around # 3.1 million at current exchange rates)-- making it over three times as costly as the # 866,000, 903bhp McLaren P1.

On the British market the model will be priced at # 18,825 or about $ 30,000 at the current exchange rates.

Prices start from $ 79,968 (including 19 percent VAT), which is equivalent to $ 89,256 at the current exchange rates.

Ford also announced the new RS is now available to order with prices in Germany starting from $ 39,000 - about $ 43,000 at the current exchange rates.

The TT RS Plus Roadster has a list price of $ 63,500 ($ 84,500 at the current exchange rates) with the manual transmission and $ 65,650 ($ 86,000 at the current exchange rates) with the seven - speed S tronic.

In Germany, the TT - RS Coupe equipped with a manual transmission will be priced at $ 60,650 ($ 80,500 at the current exchange rates) and $ 62,800 ($ 83,500 at the current exchange rates) with the seven - speed S - Tronic.

Pricing is expected to slot in at around 26,000 pounds in the U.K., or $ 35,114 at current exchange rates (1/10/2018).

Japan will be receiving five of these special 2017 Corvette Grand Sport Admiral Blue Heritage Editions at a price of 12,800,000 yen which is equal to around $ 115,000 USD at current exchange rates.

Prices for the new A3 Cabriolet will start from $ 31,700 (about $ 42,000 at the current exchange rates) for the 1.4 TFSI version.

As far as the price tag is concerned, those interested in buying the 2015 Subaru Levorg will have to settle for a starting sticker of # 27,495, or $ 42,840 at current exchange rates.

The E350 CDI Power Diesel Coupe is priced at $ 58,534 (roughly $ 75,800 at the current exchange rates) and the CLS 350 CDI Power Diesel is priced at $ 68,879 ($ 89,100).

On the British market, the 520d will be priced at # 30,435 - or about $ 49,000 at the current exchange rates.

The two new models, Tamura and Venture, are priced from # 15,995 (about $ 25,700 at the current exchange rates) and # 17,495 ($ 28,150 at the current rates), respectively.

Taken together, the whole package is available at a total price of $ 3,231, which is a little $ 4,481 based on current exchange rates.

It will only be sold in specific countries in Europe and will be priced from $ 35,500 (or about $ 52,000 at the current exchange rates).

On the German market the seventh generation Golf GTI will be priced at 28,350 euro - about $ 37,00 at the current exchange rates.

In the German market, the seventh - generation Golf GTI will be priced at $ 28,350 (about $ 37,000 at the current exchange rates).

However, opting for the slap - paddle gearbox shoots the A6's price up $ 2,250 — roughly $ 3,000 at the current exchange rates — making rowing your own gears sound evermore attractive.

In Europe, the AC 378 GT Zagato will be priced at $ 109,990 - about $ 145,000 at the current exchange rates.

It's tough to speculate on a U.S. price, but # 17,000 is about $ 26,671 at current exchange rates.

Prices will start from $ 14,490 — $ 19,700 at the current exchange rates.

In Japan, the model is priced at 3,528,000 or about $ 45,000 at the current exchange rates and will be offered in both sedan and wagon versions.

MCA will limit the new Rascasse to only 15 units, each carrying a price tag of $ 500,000 - about $ 660,000 at the current exchange rates.

UPDATE 05/18/2011: The Nissan 370Z GT will be going on sale in the UK on June 1, 2011, for a starting price of # 35,000 - or about $ 57,000 at the current exchange rates.

In Germany the model will be priced from & euro72, 200 - $ 99,500 at the current exchange rates.

The model is priced at # 9,575 ($ 14,400 at the current exchange rates) for the coupe and # 11,075 ($ 16,700) for the convertible.

Lotus will build just 20 examples of the 3 - Eleven 430, each priced at # 102,000 OTR in the UK (approximately $ 142,000 at the current exchange rates).

The model will be offered in Pure, Pulse, Passion, Brabus, and Brabus Xclusive versions with pricing starting at $ 10,275 (about $ 13,500 at the current exchange rates).

Price wise, the sport and design trim levels will start at 30,100 euros, while the high - end Q3 S line competition will carry a price tag of 33,050 euros (at current exchange rates, 09/15/16, that equates to $ 33,847 and $ 37,165, respectivPrice wise, the sport and design trim levels will start at 30,100 euros, while the high - end Q3 S line competition will carry a price tag of 33,050 euros (at current exchange rates, 09/15/16, that equates to $ 33,847 and $ 37,165, respectivprice tag of 33,050 euros (at current exchange rates, 09/15/16, that equates to $ 33,847 and $ 37,165, respectively).

In Germany, prices start at 38,500 euro (around $ 50,000 at the current exchange rates).

It will be limited to only 50 units and is now on sale at a price of # 39,990 on the road (around $ 64,000 at the current exchange rates).

The supercar will be priced at $ 1.2 million (about $ 1.6 million at the current exchange rates) and its official debut will be made at the 2013 Geneva Motor Show.

As it stands, Toyota has priced the car at $ 19,950, which is around $ 26,000 based on current exchange rates.

On the British market prices for the new Leon SC Cupra 280 will start from # 26,940 - or about $ 44k at the current exchange rates.

It will be priced at about 11,000 euros, or $ 13,510 at current exchange rates.